syre-20260825

0001636282-26-000105.txt : 20260825 0001636282-26-000105.hdr.sgml : 20260825 20260825160439 ACCESSION NUMBER: 0001636282-26-000105 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20260825 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20260825 DATE AS OF CHANGE: 20260825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Spyre Therapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 261315697 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 6176515940 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Aeglea BioTherapeutics, Inc. DATE OF NAME CHANGE: 20150311 8-K 1 syre-20260825.htm 8-K syre-20260825

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________________________________________________

FORM 8-K

_______________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 25, 2026

_______________________________________________________

SPYRE THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

_______________________________________________________


Delaware	001-37722	46-4312787
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

221 Crescent Street Building 23 Suite 105
Waltham, MA		02453
(Address of Principal Executive Offices)		(Zip Code)


Registrant’s Telephone Number, Including Area Code: 617 651-5940


Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_______________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 Par Value Per Share

SYRE

The Nasdaq Stock Market LLC

(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01 Regulation FD Disclosure.

SPY072 SKYWAY-RA Sub-Study Topline Results

On August 25, 2026, Spyre Therapeutics, Inc. (“Spyre” or the “Company”) issued a press release announcing topline results from the rheumatoid arthritis (“RA”) sub-study of the Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases.

A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On August 25, 2026, the Company announced topline results from the RA sub-study of the Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases.

SPY072 SKYWAY-RA Sub-Study Topline Results

The SKYWAY-RA sub-study is one of three sub-studies in the SKYWAY basket trial and is a randomized and placebo-controlled study evaluating two doses of SPY072 in patients with moderate to severely active RA with inadequate response to conventional or advanced therapies. The primary endpoint is the change from baseline to Week 12 in Disease Activity Score in 28 joints, C-reactive protein (DAS28-CRP), and the secondary endpoint is the proportion of patients achieving an ACR20 response at Week 12.

The topline results from the RA sub-study of the Phase 2 SKYWAY basket trial indicated that both SPY072 Low Dose and SPY072 High Dose demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (ACR50). SPY072 was well tolerated, with a safety profile consistent with the TL1A class. The results provide proof-of-mechanism for TL1A in RA and support its potential in other autoimmune diseases and as a combination component, but did not meet the Company’s internal bar to prioritize advancement of SPY072 as a monotherapy in RA.

Efficacy: SPY072 Low Dose demonstrated a statistically significant benefit compared to placebo on the primary endpoint (change from baseline in DAS28-CRP) at Week 12. Nominally significant improvements versus placebo were observed on the secondary endpoint (ACR20) with High Dose and on the exploratory endpoint (ACR50) with Low Dose. Results were generally comparable between advanced-therapy-naïve and advanced-therapy-experienced sub-groups.


Endpoint (W12)	SPY072 High Dose (N=48)	SPY072 Low Dose (N=48)	Placebo (N=47)
ΔDAS28-CRP	-1.5	-1.9*	-1.3
ACR20	63%**	58%	43%
ACR50	31%	38%**	19%
ACR70	13%	4%	2%

*p<0.05 for SPY072 versus placebo **nominal p<0.05 for SPY072 versus placebo

Both doses of SPY072 achieved target drug concentrations and provided complete and durable suppression of free TL1A through Week 12, suggesting complete target engagement.

Safety: SPY072 was well tolerated, with a safety profile consistent with the TL1A class. Rates of adverse events were comparable between active (27%) and placebo (36%) and generally mild or moderate. One Serious Treatment-Emergent Adverse Event (“TEAE”) occurred on each arm, none deemed drug-related. One death occurred in a participant receiving placebo. The most common TEAEs were infections and infestations, occurring in 14% of SPY072-treated participants and 15% of placebo-treated participants.

Next Steps

The Company remains at the forefront of evaluating potential first- and best-in-class monotherapies and combinations in immunology and inflammation (“I&I”) with numerous expected topline readouts over the next 12-18 months to prioritize programs for further development:


Trial	Indication	Asset(s)	Expected timing
SKYLINE Part A	Ulcerative Colitis (“UC”)	SPY003	September 2026
SKYWAY	Psoriatic Arthritis (“PsA”), Axial Spondyloarthritis (“axSpA”)	SPY072	4Q 2026
SKYLINE Part B	UC	SPY001, SPY002, SPY003 SPY120, SPY130, SPY230	2027
SKYLIGHT	Hidradenitis Suppurativa (“HS”)	SPY072 + IL-17A/F	Late 2027 or early 2028

Forward Looking Statements This Current Report on Form 8-K contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K, other than statements of historical fact are forward-looking statements. These statements include, but are not limited to, statements regarding: the efficacy and safety of SPY072/our TL1A antibodies and their potential in other/a range of autoimmune diseases and as combination components; the Company remaining at the forefront of evaluating potential first and best-in-class monotherapies and combinations in I&I; the expected timing of topline results from the PsA and axSpA SKYWAY sub-studies, SKYLIGHT trial in HS and SKYLINE part A and B in UC and the potential further development of these programs; the timing of and the Company’s ongoing development programs in inflammatory bowel disease and HS; and Spyre’s ongoing and future pre-clinical and clinical development activities. The words “opportunity,” “potential,” “milestones,” “pipeline,” “strategy,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “might,” “plan,” “possible,” “predict,” “should,” “will,” “would,” “can,” “likely,” “aim,” and similar expressions (including the negatives of these terms) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs and involve a number of risks and uncertainties, many of which are beyond Spyre’s control, and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s clinical trials for its product candidates; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the topline or interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described in Spyre's most recent Annual Report on Form 10-K, as supplemented and

updated by subsequent Quarterly Reports on Form 10-Q and any other filings that Spyre has made or may make with the Securities and Exchange Commission from time to time. You should not place undue reliance on forward-looking statements in this Current Report on Form 8-K, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This Current Report on Form 8-K does not purport to summarize all of the conditions, risks and other attributes of an investment in Spyre.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits


Exhibit Number						Description

99.1						Press release issued by Spyre Therapeutics, Inc. regarding Data, dated August 25, 2026.

104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			SPYRE THERAPEUTICS, INC.

Date:	August 25, 2026	By:	/s/ Cameron Turtle
			Cameron Turtle Chief Executive Officer

EX-99.1 2 spyre-20260825xexx991.htm EX-99.1 Document

Exhibit 99.1

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis

Sub-study of the SKYWAY Phase 2 Trial of SPY072

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)

SPY072 was well tolerated with rates of adverse events comparable to placebo

Magnitude of effect did not meet the Company’s target to prioritize monotherapy development of SPY072 in rheumatoid arthritis (RA); results support the broad potential of Spyre’s TL1A antibodies in autoimmune disease and as combination components

Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for Q4 2026 and for SPY072 in combination with IL17-A/F in hidradenitis suppurativa (HS) in late 2027 or early 2028

WALTHAM, Mass., August 25, 2026 (GLOBE NEWSWIRE) - Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced topline results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (ACR50). SPY072 was well tolerated, with a safety profile consistent with the TL1A class. The results provide proof-of-mechanism for TL1A in RA and support its potential in other autoimmune diseases and as a combination component, but did not meet the Company’s internal bar to prioritize advancement of SPY072 in RA.

“The SKYWAY trial was designed to explore the safety and efficacy of TL1A inhibition in a range of rheumatic diseases to identify opportunities for indication-leading products. The results today do not lead us to prioritize SPY072 as a monotherapy in RA. However, the favorable safety profile of TL1A inhibition alongside demonstrated efficacy across inflammatory bowel disease, HS, and now RA provide increased conviction that our long-acting TL1A antibodies have potential in a range of autoimmune diseases and as optimal combination components,” said Cameron Turtle, DPhil, Chief Executive Officer at Spyre. “We want to thank the patients, investigators, and site staff who participated in this study and look forward to results in PsA and axSpA next quarter. Additionally, we are excited to have initiated our SKYLIGHT trial of SPY072 in combination with IL-17A/F in HS, our fourth investigational combination of validated mechanisms in autoimmune indications with high unmet need.”

SKYWAY-RA efficacy results

SPY072 Low Dose demonstrated a statistically significant benefit compared to placebo on the primary endpoint (change from baseline in DAS28-CRP) at Week 12. Nominally significant improvements versus placebo were observed on the secondary endpoint (ACR20) with High Dose and on the exploratory endpoint (ACR50) with Low Dose. Results were generally comparable between advanced-therapy-naïve and advanced-therapy-experienced sub-groups.


Endpoint (W12)	SPY072 High Dose (N=48)	SPY072 Low Dose (N=48)	Placebo (N=47)
ΔDAS28-CRP	-1.5	-1.9*	-1.3
ACR20	63%**	58%	43%
ACR50	31%	38%**	19%
ACR70	13%	4%	2%

*p<0.05 for SPY072 versus placebo **nominal p<0.05 for SPY072 versus placebo

Both doses of SPY072 achieved target drug concentrations and provided complete and durable suppression of free TL1A through Week 12, suggesting complete target engagement.

Safety results

SPY072 was well tolerated with a safety profile consistent with the TL1A class. Rates of adverse events were comparable between active (27%) and placebo (36%) and generally mild or moderate. One Serious TEAE occurred on each arm, none deemed drug-related. One death occurred in a participant receiving placebo. The most common TEAEs were infections and infestations, occurring in 14% of SPY072-treated participants and 15% of placebo-treated participants.

Next steps

The Company remains at the forefront of evaluating potential first- and best-in-class monotherapies and combinations in I&I with numerous expected topline readouts over the next 12-18 months to prioritize programs for further development:


Trial	Indication	Asset(s)	Expected timing
SKYLINE Part A	Ulcerative Colitis	SPY003	Sept 2026
SKYWAY	PsA, axSpA	SPY072	4Q 2026
SKYLINE Part B	Ulcerative Colitis	SPY001, SPY002, SPY003 SPY120, SPY130, SPY230	2027
SKYLIGHT	HS	SPY072 + IL-17A/F	Late 2027 or early 2028

About SKYWAY-RA

The SKYWAY-RA sub-study is one of three sub-studies in the SKYWAY basket trial (NCT07148414) and is a randomized and placebo-controlled study evaluating two doses of SPY072 in patients with moderate to severely active RA with inadequate response to conventional or advanced therapies. The primary endpoint is the change from baseline to Week 12 in Disease Activity Score in 28 joints, C-reactive protein (DAS28-CRP) and the secondary endpoint is the proportion of patients achieving an ACR20 response at Week 12.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

For more information, visit Spyre's website at www.spyre.com.

Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding: Spyre’s ability to achieve the expected benefits or opportunities with respect to its product candidates and combinations thereof, including its ability to develop next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients; the efficacy and safety of SPY072/ our TL1A antibodies and their broad potential in autoimmune diseases and as optimal combination components; the Company remaining at the forefront of evaluating potential first and best-in-class monotherapies and combinations in I&I; the expected timing of topline results from the PsA and axSpA SKYWAY sub-studies, SKYLIGHT trial in HS and SKYLINE part A and B in UC and the potential further development of these programs; the timing of and the Company’s ongoing development programs in inflammatory bowel disease and HS; and Spyre’s ongoing and future pre-clinical and clinical development activities. The words "opportunity," "potential," "milestones," "pipeline," "strategy," "anticipate," "believe," "could," "estimate," "expect," "may," "might," "plan," "possible," "predict," "should," "will," "would," "can, " "likely," "aim," and similar expressions (including the negatives of these terms) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs and involve a number of risks and uncertainties, many of which are beyond Spyre’s control, and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s clinical trials for its product candidates; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the topline or interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described in Spyre's most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and any other filings that Spyre has made or may make with the Securities and Exchange Commission from time to time. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.

For Investors:

Eric McIntyre, Spyre Therapeutics

SVP of Finance and Investor Relations

Eric.mcintyre@spyre.com

For Media:

Josie Butler, 1AB

josie@1abmedia.com

EX-101.SCH 3 syre-20260825.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 syre-20260825_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Soliciting Material Soliciting Material Written Communications Written Communications Local Phone Number Local Phone Number Amendment Flag Amendment Flag Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Security Exchange Name Security Exchange Name Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, State or Province Entity Address, State or Province Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two City Area Code City Area Code Cover [Abstract] Cover [Abstract] Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Central Index Key Entity Central Index Key Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title of 12(b) Security Title of 12(b) Security Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, City or Town Entity Address, City or Town Document Type Document Type EX-101.PRE 5 syre-20260825_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_1a.jpg GRAPHIC begin 644 image_1a.jpg MB5!.1PT*&@H -24A$4@ D< "." 8 [.ZRB 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.26.1

Cover Page

Aug. 25, 2026

Cover [Abstract]

Document Type 8-K

Entity Registrant Name SPYRE THERAPEUTICS, INC.

Entity Incorporation, State or Country Code DE

Entity File Number 001-37722

Entity Tax Identification Number 46-4312787

Entity Address, Address Line One 221 Crescent Street

Entity Address, Address Line Two Building 23

Entity Address, Address Line Three Suite 105

Entity Address, City or Town Waltham

Entity Address, State or Province MA

Entity Address, Postal Zip Code 02453

City Area Code 617

Local Phone Number 651-5940

Written Communications false

Soliciting Material false

Pre-commencement Tender Offer false

Pre-commencement Issuer Tender Offer false

Title of 12(b) Security Common Stock, $0.0001 Par Value Per Share

Trading Symbol SYRE

Security Exchange Name NASDAQ

Entity Emerging Growth Company false

Amendment Flag false

Entity Central Index Key 0001636282

Document Period End Date Aug. 25, 2026

Cover Page	Aug. 25, 2026
Cover [Abstract]
Document Type	8-K
Entity Registrant Name	SPYRE THERAPEUTICS, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-37722
Entity Tax Identification Number	46-4312787
Entity Address, Address Line One	221 Crescent Street
Entity Address, Address Line Two	Building 23
Entity Address, Address Line Three	Suite 105
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02453
City Area Code	617
Local Phone Number	651-5940
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 Par Value Per Share
Trading Symbol	SYRE
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Amendment Flag	false
Entity Central Index Key	0001636282
Document Period End Date	Aug. 25, 2026

XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://spyre.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports syre-20260825.htm syre-20260825.xsd syre-20260825_lab.xml syre-20260825_pre.xml http://xbrl.sec.gov/dei/2025 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "syre-20260825.htm": { "nsprefix": "syre", "nsuri": "http://spyre.com/20260825", "dts": { "inline": { "local": [ "syre-20260825.htm" ] }, "schema": { "local": [ "syre-20260825.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd" ] }, "labelLink": { "local": [ "syre-20260825_lab.xml" ] }, "presentationLink": { "local": [ "syre-20260825_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 24 }, "report": { "R1": { "role": "http://spyre.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "syre-20260825.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "syre-20260825.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Three", "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001636282-26-000105-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001636282-26-000105-xbrl.zip M4$L#!!0 ( )*@&5V$AQ?VI!( *=Q 9 U=ZW/3R++_?O^*N:1@ ]S92!KMS"C&YZ\_W3TC2W[M)AR6&&**BF-I7OWZ=6NFU7DVLEGZ_-E(\/CY M_SS[WW:;O511F8GABB?/G\7RFLGXYP?R8%?T>P?=L-_C?*GR_OQL?BH-D+PG_%3R KM#<]3%VDHJ?'V0R;X\$SG^TLUO8X[&,[>@H MZ'8?/J!VSY\E*K8Q M4'+4AQ8/W-!5]TBE2A]M=>G?,=YI)SR3Z>3HIQ,8)M3RIY;AN6D;H67B&ACY M;W$4!# ;?1T[.O:A?RIS4=$5])"8T\\C&4K+#@\[P2PEBS2$REJ5'1W"P VJ M@MX2LH *F0T93RV((.-#\:^ =WXOA@^8T='")3=+S>_/Q[,SH@2NA;8RXJF? MA29TMROA'$#'I;+\DM6O$&]CV$:G"(0G]+>37- #R9V#@0AV,1*:%Z($WA@V MR'-5YI$P[$(5V(.="5.FUK!$JXS9$5P8B3+C5LF8#;0=:6FE8>M+8QFVC2WC M"5,)+?_\GY\N!Y_8AQ$W@O78A98\Q7OG'SYU]WN+A*R)(&FD(VFA>31#]LX\ MV?U#(/N%LB,6*P."K&F+1:9R8S5AIK$-QB5P+F$Y'*8^HR.#GK=>$RSV,F/A? *5 NN"'RN% RAW5LB\ZP MTV+0<+?[^-9"^(Y$1WCJA37FAHU%F@+S4^%$-I8@5/R5A,IC #3087$M\JFP M>)B*AKB^([+?<=! ,%32*9$D(K(L!HS)E669$);T[ 2)S">/M@YZP?ZQ819@ M&&\IU$"%4/1O 8H)?0C4)J#RUR)5!44+M2& 0NH:Q?@4Q;;/!H\?;>T>'C/M M4<^41:&TFSS4BL>L4!8&JT #$72ZFHNWP0#4V$H(("0(":;A)4R1925802R- M0,Q!/>!OOMP:.M MG?WC5]A@)&/-(9:BP5'\)5@L*W@]MYCK^^ M]ZW"M\O!VXO7@WWO[XX9>]/+\\OWYR=3O'W M[UGC*?!!(D>K&8(7U$Y/')B@1=L1MTRDXAIU #$! MAD # MA,0382>P'I7(E,1J@$@4%C7 M9)CB%(T,%3AJ5"@S[6,D1:EDC;\SP12(TU& MTJ5N0,G9@%9:^2+D4^V%X#YYNR6NQE2^AB_W-BT6EC=PLA(=1PY3A5S/N5J( M03BHVZ)[/1MTU@+S%O DV 4\0=)ZW>.+^G' Z3I*.1:HF$X#G6YX2W=B)I5) M4&TC,A\O(WH$1N:BSX<8#342[B[:"0XK\5%=)M"?!%JBKX$[*')XC(>A<:1V M*GB,5@?*$9>1G5,=9^^Q(M%A4U::.>%X:9#\FS&1$P][K<8 >;I%U"7\6KG@ M<4Z=EY#(4Y4/#>KMC'5/N<(CK0RJ39+R+'.6%<)D:<6$%GM][HPO5V/4[LH. M9(X[.@8& RNZEI%'7\!<56J&T[9Y1% T'VJ-^+68-8J&%/[$,E1A 4;2%=%8 MBQ0E. :F@)&<\$QHN']1:IL"$2\_C"3 ]\E(BH2=?A81N"58Q:_(![1'ZYQ6 MAWEUNQ2@8#E%JT!3?N5@;(K@,K\6 (Y#9)AQ[#'2DHM)$C8>@6PY;F#(@M@M MD3,8HA"08^M4*8I^QNB/8))*5: E1%$^B()8B?P;^Z.$T83NL$$7WBSF;'\)0%6.]AO!%@H>QPD@1]P MNR:;UC#3'P8&[R-CFGB*C?.!=6TSQLTX E-G99X!GN5"Q)U*BFN!2"NV*0B& MVF +4S/RXEN+12^'42_TMV#$+\'OS\(!_VMWO\K;-]U[Y9)OXN?1Y"Z%N&)! MK\/>JTSF"S-#0 580P[+,'Q^!M2L9AX+C"Y"8,8UZKE;1QTUU"MQX8/3M=>H M:T0]VI?OM"RFJ$(*UZWB66>ZOT:SNZ 3%]UXG ^%'0N15\XV;GL@;^?\T5:O M?WA\[1\JY^_7P6),,=]0J[( /[+R<;&Y7UTH0[!PI$6*#T!B80>[ZN6W1;MU M%QX:E99VL:/]^3/K7%]% MCXZ%;H/UI+PPXJCZY1BFP.YW#8.^[&7:WTSU8?;LY[%-BL&,RB-% M7/OS@_Z#.4FG(@%(*P W%3@;5@&FOTM[_ LW"QYC=';4Z^SUX"8V *FZWYJG M 3CV@D:HXAON@B-2GTY!Z#+HU5NHGGWKQIDU.3YHN+@IRJ_!.<=R7[S]_M'6 M7G"\R=B[>:XQQKPX>Y/2VXD^?UEDK]_/F[5I@X$&\?3 MIX'U<').7>Z>.6U8W88C]SM='>;^9IS![3NWY,GN3O:93?IM,;'YTL3YG@TD@+/GWUJ MH]0)E[#TW:1+K$KLOW4FX=F*-P$H MDV!9_D!$^4G;O?V'+J6ZLJOM_IZ_4N,ZZS%4]J;6YS+>LN4H6R1#-.O8&Y/I,SQ-8&I3>!72CJ!"RT_"0X%LP0[#VLC M:UO_WF!C9C<"R F;^;F7MEMK6WB/F5V@,L4ZV\%%G6,*\LZX1/&YU%. <9%H MY;))&YG'=69?(K6Q;1)6",)NR[Q-YM#(<)0^O:^1248I8V\>;?4/CM\X8\I+ M3.8#5<8DF4&[Z+07RC3-2#CM!]XLR4H+#SO[^S9(Q;CGL7N_K#]O?[^S\#?DS MP4%GO]?;9*3T%8X3=-E\M9>F.AR\&EC8(U,/#-HN;>4-EQI;''1ML4&=FY^8O!Q M SHWBGU>;,QL$_O<(O8)6K2'VNWYSSYN7\%O0:]+5X*^^^SUOUJ*RCV *ZPF MLLD^^%(L^^7UQ?=QGKX>/'M]ON'6K0_M_F_F-?8?(AUA/?C[=GDUI1MG**S# MJ=L@5*5ETU?XU_SHK2XU4-D(>J7%A^ <7T>!=4A\'6=!K@@:2?L/%)T1LUZ!^QW*BO48B=M+?R* M"ZVL@+O;S0(&>;RJZH!?"/3"FC$^L6/*'YWZUOIJI,E5$#GWI9'9GJ M@'X]]']!F>CD_555WTSFP-R,%MYBU])(.^7O6(14$@CT8#P>=PR5%P)";T=7 M1=&]K?;QC6"-\A=>N7I,[;=*75$-/0OFEBTM];D6NMA#8#N!J) #J)CI8J?E MIBBM$'Q+Z@IYN=)S6,Z*%27Y8VADE4;XF]7DC$\HH\U*"[H"!M[?.?;%JMJI M9TX]']TFC^[#CTSP')OXZG^)P% @14=9:E<^+>5CJJ*%R(,M":)*7511157$ M#:!'AW@/,R@-)0>5 $DNU>>WG,I>D90,^Z E@>UY/UA9B^JUR;7V'/LM5^24&3LO68<$UEX$YC4')OU"ULOF"?Q=.D%WO[M9!H2-^A;S+#S]FWJ7+R:AGKIU5#S!2Y5/E38I#G@-*#:$OK+1Y*5)E M&C%6[FODLGK_O@D@C?G)J@\U.IY MR4F%5(03H0GSM#V,1K;Q_@&I05+E75^K%(O0859M"):)E4^EN7)WL1XQA1.6 M0"!#5%-8T%)2RCCFIT_4@NE,P9[*ZKD"M\:465'Y)B"70@I>HAE&M@03JC ) M@5YH"CZ0<>"I0H@@T&=(2FZ/99((HLNC%];O\\(4E/:.?D2B5YUXGJ]F6,72 M%13_=00PVQP'\$/!!P4RN$:(#<4O@C2?1';I0%&C<@-**>2MRB7S$V#O F% M V,*!_S;$8#"35^$.S$\$R3IA-X%FNL]_^X$M*N%3N$JN0;OR^97H05BK'"U MX]'[+WJ5AK\'AK@0\$*#?K)!#/Y&&O^V#C1, 44KATO;2,:5D1]396L8/<2_ M7P2J5[L1IY&+BI' 3$I3D>)(R]"]05$]'=)+$O@"!9 XR',TB#,B!.=YA:%J MT&W_LX51"+X?E)**^#VZLG!%5D%AP&4;\4>)HWQT-6+!8MQ ICG21^?MT9K) M/!.(Q/*A-TVW-3*"J3(>N]K=8*P9OQ*UYC6B:ASI]+/?9#O!G1'W[I(S3Y0W M%LV%SP[[I$KF()[$39N+&,"7&)*DD@P>>ZX&N!6/,@Z0($KF5S [BQ.'QMB M'[U.R'Z)(J(=OOP!;):)K KR8D"(>J$QC"3K(YUS($0;B6"$N$$!YMA8$D;: M,O<;*36RTW.)1:;AEF4483(5,CPN7?Q-_,0+3GQD#EI43S7XI)#_F8OYHE=9 M[GJO<-?OE;RAG24PAIFW*[[E]A^]C7B'6Y"X:WH*3]KL7?0FMZ XK9MOGWZS MS*7__X!&] HP&HV =NZ\X !34A=0K $/.UDDB8>/MO8@A*PVUKX_^Z@VG=@[ M"(SY7=B&^XL==VL;M(9_*",%>U':%*OWW$]I%\!#S,4SZU5;+VV M;I^Z/Y3XE/Y XW\ 4$L#!!0 ( )*@&5W]#'Y'4QP *3* 1 NQ& MJ$@&_NL7=K[P@@F_&[C2[[]^T6@WS\Y>_./TIU?_85E_O;DZ9V^#;C(4?LR: M2O!8N.Q6Q@,6#P3[%*@O\H:S2X_'O4 -+4M_U@S"D9+]0Y01R']:.CV]O;_&TQ'ZC^D5VKU8[NL$U.-ZK+N]B*1'>J,?S. M]X.;(^E[TA<(FZ-8<3_"I?,8@'GD%.RR5:A:17O17+1(IU"PC_[Z\[S='8@AMZ0?Q=SOBO0K5XR_HF'3 MY<(+'*2<=0\OY;)5%7!5TQW#Q+_MU+A9W\1'M]]'I M3S_]]"J6L2=.HY$2%J)LH>J47QWIAZ^.=->=P!V=OG+E#8OBD2=>YUP9A1X? MU?W %S !>5?'AD+I?TK7%3[]$]Y? $IV=7CW\57HO MQ%PDLW<>[^>8=%_G>I93S)WVN!>)5T=3':W1;\N'98R:T+'BWIGOBKL_Q"CK MOY0[+0!:5(H5I^K,#7(TO1 E>D(!IQ#1 OCCOM0C0BV8!J-]JL< ]=>Y2 Y# M#_>7G@T4SG(*U/F[R(6-H/'&@Y@QHR!1](OPKFZ62@O I:;/!:TS_25=_-V3 M0C&:DUA(R,VS/Z;7/_OQ:?IHNO<0P!.XZ2_ =A6_!BA]:R"0>]=+ MY3 ^N95N/*C;A<(O.6IW^BH*.2!$1^&.Z7_K3N:[XJH/O<5!6*] 3SA_BWNR M[]>[ %"AH,.8=SR1MN\$"M9A=0//XV$DZND_3E)2TUS0HH].3.^=((Z#81VG M"C(MEEWNF4%H//UZO(I\0:\D!GC%;CJR>9V'5T?SSVO5?*VP^%4A;]/S(^I/ MI2\- (MAG*-O8"4(J=>Y8FYFL6;ZT)*Y08+ ^!EF>!)R%^5QOX9?7X4'JC^HMK.00"OQ"W["H8K, #]O-6K/(8N:%_,JFT'(?SQXNRZ]9:UKQO7K?8THDQ,? =9NGWVX>)S9.RO-_E.C_?[L MXO?K#Q>'[&V^F0>5JURJ+9WQ"B2YL0449A906KB __NZ_ZV])XLXUFXAXKL/ M5W^RU25[JI=KU48+=.#H5>N/>4'^;+%AFRMORP]7U$YKX M9:*BA(,=& >L+;IH?#"[R +%[/*!^Y(%/3(*X56B9"QAS-9==P!*HF"-;HRO M[5JQ](06C.H83OM*A(&*V4'Z6W!0R$04,W K&BU\)]6?\*XKTD+:^E=;\< MTV8=Z&YW<=V%)]80NAC@9Y;+1]8(AK:$GZGON=-&TD]@)D[YD&SM6CR_@3;KM8!2V+S]?M=CU^]95X[+U\?JL MV3YD9Q?-_"YR_N-\>27@'+3N./ )A(&FNG3MC$>L'8HNFF0NDSX[BR/6'(!E M)=3+75CAXR-X11L:3\&8*CIYIUB\UYAZK*Y*JYAXR^RYU&)S\A7@-FBV,1LQ M'_\UCWUSX W"[XF0 1QF0E=%-95O%XV-G M@9=N#[-X=,WOSHS;KDOH.0W 2NZT5+%*1=LYKA[?"\$G1.4K"U8B5534/X"" MKMA_@WX>N9(T>#**0=I.D?;+)X93*P""D.J@&0R',L*X%T,B8QI)?L#EZGT_ MNVJSUC#T@I%0M-'3),(N@OS+1<@_X\5$C^)2-^:84WQ>0"BF0*B!W9A(D 1VH7P_"#; ")=1W)[T-Z3QF!UNPC\_ MJ.O@-M.O[4+N]!/WX@$?SN[RX1H>JJE12(/XH"Y!F9<4VC=#V;G3/QN[BTO/ M'#TQX#NP0]EVVK7"L55N64>SS?94ZVHL)]$<2L$88>S .@O08S MVXD8RKM 8ZR"PJB*&9^&IEWR&0/ R=^7[BLC8H<.^=1; *<^U#*)(%N>4'- M@>A^H?@Y#T,5A$JBRZX3W+&.\();W#A\B?O)JM8?K"<]9*0R8A)36EW8T#A@ MD1PF7LQ]$221-V(1CV74&]&7YH.@ _NFO3\F7J_&<;8$^E&,^Z/T70\847"+ MWZ$;7Z+C+*JO%%-^2FS.SM>*]W.YE1EF.5\]?F3%8$7$_02CX$@1H"SW(VM] MO%W3,OFD9 R8BB[8Q#<>R&@ZXZ$G[X1K4<)S)H;+N=/@.X8\OAF.&V !$@# M'EC+)'Q8.)%T'T$*8?/Q-,!QA9W0D@/= MEZOAO6Z[Q_S'Q?RS*$J$6@O_JWO\7X+_16&5#KJKX;]I^Y5NQN-MVZ]+SIR, M]39M?PD%%ERX*,.:&(.QQP 8]5U-!ZS5\M52=>ULP&K>*2PVLI897\N?EPJ5 MC9AQ=BU?J#H[-BF"5/GQG'%ZL[MJC82?P#M8*6/V00+DP>>.$)B(5'\!!;P<2GHS9[#KI?H9KDD<+ !"! M#>-.']#<52!]LRFK)=3(=CI$@9D64\N=HAX$@&W'0??+(?M/'GQ;?N\#./KM&[-(7B:VONFN$,FBEDQX0*H'!\OFI].-9TG[]C Z4'IN^"1R__6U,;^Y.J+B-GY>7,WD]@6 M ^O K.%W+^AP#W1;#[1;LY:7&XBF;CE8<^:[:,P(UAFQ+@5N8$I?0- (RJ^> MB:K(B,'LP!+"6?=97P6W\0!MHA C+3QBKNC!$'2R2;MX"^4%ARG'9RB+[.#7 MG^W*\0G&VHNU$_+VIM_ :(!F(1Z-P@"@MJ^#YSMF\TN<:?3_2>7R<. MM.4-:BT!=CKCK?D8OBJ%,YW][S3YII[[@^X%Q[G/O;!S6W36NX"5H@?/BP+ MWBAQ(R/X#LB2^UUT5/-N%T\Z86,L;N1RY48Z)NHNL]N+!SRSVR<)+?](6!@\ MA O&V$>1_#1/%CZ9,BUC2#]0FV*U,C['DV5\MN[*.HO%D!WGP0"X$OW$T[D% M[]ZRMS+J>D&4*)&?6]B]J_X>*Z#.ZC(&C.NN0"OMR\^%8X>U__C\J?'9NFJP M=M*QVG'BCMAU$&)[6&R4>'&TWM*F5#)@<:".U8N5QV"_'WPV4SK@D+7#D1(, M5$[%0Y$ B4:4LY='E:#J.(43:D#_MD^03R)K,Z^,E#(O7X+2$R7 &3DP24RV M5<"B.;!E[OO 1[O(1V,#2*4!R7HJ&&KF/A )"+H C >NX@'J*E$VA:M&-D0$ M>Q+1GA@N>SG (=)M8QT>H:H<4Z11W(!ERHF!F\T%;SN.V TBRLH(( M'E+WQN2=*H#-1"GTZINR&$CM)BL)Q7::XCG9^^SHA[-Y2QW!>HGR981M0+RR M:, ]C^0YO'(%J ENBFD]Z0DW14*4XR!]PP#V#B>82=_JBNKN(4*"#_5,#B80 M>K)QBG*'B/0!ZOBW@"^(@/]".P86@!]ZDG>DIX>BP3G8P'H^A[ 4918E)]G$B7=@9G+/#=?M=I+:(PR,^-%/#4[-B(L EG!@$WRXPV<=5"(B[KJX0,+8)$?)( M2(-"8+S&\=X#N\9$?D(!)43V!KD0"0JQ$!^0DZ/L86!_N<$0)J*Y.Q@)7=$) M++2$%1@/ K5U'&<"@>+; #3ME*UGV!3"6Z1,;;,- ^!R:"5B[JL NT( .^-= M.L@#"Z V8,.YXN\$6P&"AX$?47,8&TD"'0N@!!1J-*^1[P)P&[ 0-3.DJP@#;;"JK$[X M];G=T)%;35/I?A@'"OX->A;\?RAP-3(:DF)'GZ%3M*%UPB0DA1/A% 8X@MX: MK9$QGH#)@'DF(A,T]!DJ1@C7#C "(A*$,0#4!VVHDX Y+[7C:"APN\<",CO( MA(JJ0B[1X8KV1O"Y]S -V%E!0A2Y:U\%2?C5%O5D M"6HP[\A[6P?YSE%4SA6E'GOKR+-6&'_".U'@)?'\)P_5L=;_'62^PI#WA=4! M8?W%XCW@"'7NW?)1A$Z_20_?YJIG3W($K"#[5-RP=BU?JVSF/(W]L$=WY?2I MXSP8I9N;U?UI8*NEE6"X>R94CNQS:1S]6T/I:V6#-N&;CI++@@[V0T*#[*96 MQHX^S2;K[R!D-A,TWPC@9C7)[Q'=7W.BBRWC@XO7I>JB&/Y^?U?8WU0P/ZOM M5;K_9[S[EUH'W.E=/UZ:F/.LY-IB /WZ<\VNG&2VP&X(M@T44=@(<"R8W1XB M,Q"I_;8ID'Q7]KE#$"M^1:+VC\]YR!NPIZY)D%2*O_RV,>IZ^B!Q "3EZB][ M=K,&"I6*O^RYS6)N4]YSFRF0%.V-D=8/ I#J!MGOL^ V=NUKN,TX:W0Q;)X% M-SI>@QL])L!V!M6*:W"K/D@5W(E+R_C@DE_]0? M"RLWGIUT!1\35G 745KH*QY-NL2B) F=N7?@'/_REXL"#0S,(52KUF5WZ94QP5HSKQ<-S MXY%U#R W*)'1)(DN:K<+=+'FD:(+O+2^'8LPVH&Y/Y@YF2:)*S'D$GBI0&>[323KCM/Q>E)%L47[V $\ &EN$6E-Y,-)DY@WD9-'6<24O ?+ZX]2 M1/+XT)Q&27'_[%<^#.&_*?H3$?MXV!5)"#.0Z"#H./&3NT$">!7AUT7A JZ,9>%-GHS\V4[UH#[#I3+M"\4EPJ!T!F AC@5?AT*'1/7M:S)X^ M-3[OJ6PBHS$*\,H2V66-N9H-EU%C?(*^<8=F8CL,?'?D!?,%'OA=.VSL^=A\ M2H=VF^SYV.J1G'_N&=A*^M6;/9E-Z%?-/31FE"?[D'RV!?CRL^T4 MZ)E=U'^=8H%-^\'V;.K!"&G!.=YG@WPM#_O]_?73R&_8#9B]EZ[BKO!)Y6HG M89B0+M]>WW=:P]6$X?\+W9V;MG'C:-W/T0.R6[ ]APKMR"3Q-"IX,H; MX:_J"FDE.Q,JIW6\"]0M5RX[#X(O5"$)KU37E0$>(ZM#N_KOK^=&I6HI_I?6 M7M-KL#R]AK0*6S1>"@;D3$6@H> ^73FI"Y9@))X-N.I@R;;L-LGT[<=\.X_W M<=_@;D_4.#N'/^:^RBN!U>G&5<]JY3QK>-[DZ&:^.JC]8+&ZP%1K)I!G?4#? M\&$,YFP7XYD'(H=7#R<+*M M$GWH%^E1%W,P939TR1.=O9 %S8^"Q)1%X7XL.X&;QE+A2ZD65$4YHMI+?:H: MO0&7W]L9D68)I8V'QHVJ!R-@\AZ M^N-9I]W,5I@)_'Z 328[RP+1&!E/0^%8X:,3W HOW4'J\GW[1"\@+<\YU2F^ MZ25QHJ@J).R ] FS">SIC\F1N2Y7E57 N@VPV+'A '5X$E @1@=IN1O7F7 MF7T!/ NV'W JFOM$AE189?:YKNK2GQL"L1Y30.*Y+SK0#ZQA]G$W2#QW]B&F M70T7]*'Q;&[V?&X:0V2A1)^"#M$8RV.AAM%+!O!A M$E,V96]T#Y?4O) N..Y$5%8RZT@CF!M Y[H0$_=UG2T^_AZ+G>'+F0%2WKM\ M7&*_6,"'4J2Z1ASHK9Y(ZR/\Z:4I3#>!AU5N,+,$_> P4R6C+_HMUDQ4*&5B M8B=#\Z6L...()!UT&I#4I#(K M$; E#B:'>@A=O5;S=4_>T UO1CV:E&A88XJC.H<)1Y1A._/U;,XBM!MO.&DO M\42MN]E9*%)\A"YYC^K#M'":4!D $%JUNE: EZSA@MBB*ONZ<#Y=WYJ*:RJ. M1;+)X[=4H0YZ[B2POX!R)P:ZB(7SR( :5:#PUHNHJV1'ZVI$+"\BG6.(^8>8 M_>C[2 0SFIM=0-4-=!9,M?4(+4Q5R7TIJ;E24ELW*)+034L9@](5B;\3W,E_ M)J!2";3<]&9&D[OY3ZVO(1)T>*7RP7+ M*B:&E@I1"%L-+SRZ[L58/"[5+1V($3%16AX! G[\#7@O>S(U8U"U1R)5: M, M%8DVE:=!:% A4^")$_/#6MO2SQL89N*5*D/'"$&L>MK5Y: !^FX"O4.'!%Q\ MH/B^MD@"8<@'["D(EAT!D)8"D^:1.*Q M-#+",P8+(9&NCC@S*2:Q5!<-/\HO*+:Y8J[J26\!(\*(F2]P!2^S&=3WE MT'J4[A^'5@?HZ9?K9(O5HIKIP<7\]7B\:8N M1'6J&TGIK1;SQ>)6+D1]Z%JZK=^GEEZNL'U2@.$U9%S1#;1J6">)@JURIQ=D M,&WZ8L&-[-/.P.@M*;[A7#;Q]NYP?V)7O6^*:O JDNW?DGMO0;JE,.CUMHV6 MK_A"-4=H5G/RF'-C X67Y46HU%F8TU.H.N4[<7=7J]GY03RD*^>G[KNARX= M55YZI5'F=6=OP4H^9-ILF;DP ]0E/FM:+:?4RIY2-T6I=J&T2X2ZY=4WZ;3: M)0<;]@Q=.>:0*2(JJ/B@+!Y@>J[KCOU):"V=D6;(_GIS=0XF5C=![?_E"E'2 M'?.2K&&CU7*/Z%I9H.'30?ZMWK:[Y%#VV>\7C>N/5ZWVBG;)]LVXRXD;,_6% MGG\G4HTCL"O=W+7@)E W\8P/W=7.&>W^-"YS+,VOXP#HTNV( ?=ZQB6NW2*F M 7I.$A^^H>Z,F_G?PEW)?#9.@"=Q[+.4+Q+[:*_?(X>FI/.LKEKL^GWKJG'9^GA]UFR#.G?1S"_7 MT?8;N_[X/Y V25@#BI.HKZ%/;J3$^&-+V!E39FV7S)/9W3<3Y6=^I'4=14>L MR;&RA<^N$Q5[8ITL\:?+WS;>\=)7)E+3(P,C8P.#(U+GAS9,U474_;,!1][Z_P\CPW7U!(18LT$-*D M;D,,--XFQ[Y)+1([LQU:_CVV&Z^4 E+WM#PY]YYS[STWQSD[7[<->@2EN12S M*!TG$0)!)>.BGD5WMU?X-#J?CT9GGS"^_W*S0)>2]BT(@RX4$ ,,K;A9(K,$ M]$NJ!_Y(T'5#3"55B_'/5:C5>Y6.IZCA+DC2^_[;XZ:'1@&VX>-A!KTO5 M!'P>NW1)- 2X?E+P%ZZM3!A3V<9.9W*:'4>(&*-XV1NXL@NYA(KTC9E%O?C3 MDX97')C==@-NGSN %VE#5 WF.VE!=X1^V&T^0LBIYVTGE4%BC[,OB MMB*!6 MT&9E"TF)\4YXE^+><.!A%\)IAO-TO-8LBO]AANU2#YLA\ Z?P1?30,>U?(P9 M<+?"X[?;Z_?@[H#=8;1(=9U7%1R$[ A-_@T3'\#5?#IGOD&JZ9% M4<0^:WWGR411)1OX&!QW2G:@# ?]TKB^P%)!-8NQ590*&&>.EM"V^_0P&9%_[/^AI2'ZK<4: X4[HBW-H\XFT47 MTOYZKTEM!W/QNYNO;UQPWVJ+#.5"0085%]Q;+O%/BO#V-XV19R)'/8M?$UZ5 MZC6P'V+NSZ^_[4 >(!\0*6EHWQS.VX[U+FT(AA4.5RS>O6.;]Q?WT @902P,$% @ DJ 978F\A/7*"0 KUP !4 !S>7)E+3(P,C8P.#(U M7VQA8BYX;6S%G%UOVS@6AN_[*[B>FUU@&(O4=]!DT,VT@V S;="DF,$L%@%% M4HDPLA3(RM>_7TJV$\FB9)*RE8LVCDV?][S'>GQD^B@??WE>I."1%\LDSTYF MZ,B: 9[1G"79[,_(/SSW]\OP*\Y?5CPK 1G!2] >UD\[R^]?BN3VK@38PMYFV>;1XMA"Q+)# MQB'Q @)]S!F,& EA9'E1S#V?^Z']\^TQ8Q&Q0AS!T(EBZ(2A#8F-'4BX2SFV M*6/8KH.F2?;W69<\W MJV?KY<^=]4]VO1J%83BO'WU=NDQD"T58-/_S]XLK>L<7!";9LB09K026R?&R MOO,BIZ2LJ[XS+]"[HOH-;I;!ZBZ(,+31T?.2S4X_ + J1Y&G_#N/0?7SQ_?S M7LEP7JV89_RV>FTO>9'D[*HD17E!(IZ*[.MHYK=LA08).YF)6S>,)S=7>9K0I!1M\7>149&0]&:K<3G, MA@'Q+4AMUT8HL#W$@YOR]8B^X1G\<;41KQ6&PL\T7)4]=!9\F3\4=-77A&35 MTU=9G+X)@HWBQ_E;9MK%2 ]L,3V8NYRVHJ956\Z+;1,YW6'B[2!?"A>U@R6G M1[?YXUP\43C!;G4#5C?J8[LGW+Q3^D_%)D-2T!VU6J^8TUR<;=R7L%6VN,@7 M*E;*7.556Y5+",Y 7C!>B+-'2?*MX^:/(BD%;6?Y8O&0):O3G^4V1]0.8!B[ M#G0(DQIVM3":M"*$5GRB)/! M-6BHR=?P0GW$JD\5Z>5=GO&O#XN(%]MTA<2! 2G:#GY@ ML&HY4.N!E: Z5)TZ[.9IC#L]E#2,:6'4Y\"(H$ZPR>#IL]'DIG>-/C*?%N($ ML-K3^)*2VVU>(A=!XB/1DCS+]D,OI@0Q55Y:D0\,RZL6J,3406F[WTV)L2<] M1!3M:.$A3=V(C7:DR<"0&FA2(5^@C\3GK$S*E\\+7MR*,[_?BORIO!,MZIYD M+]N Q!:!HJDX, YHZ&+;QLP*50$9T#DP+BMEL)$&*VVP%E?'9ZA2NV':DW\] MM RM:Z&F8,P(O*&XDV&H8*X)IK,W!FAIF+, *^N@Q%,-8)-#%+71I<>R1I]9*XX?2@J M%)_IG7B5^%>RX-O8V"Z%88A\&&*.4"C^>10K[^))! Z]C[>6!!M-4(EJ;.7) M:J*PF3?2J>9VGIY)O1V] 2=F>WJR@-/MZ@W8:>WK#:TS[4:?&!.OXG+]XR+) MN-TY760,!@@[$(=Q&#O4%WA9>FU)HC)-?UHK_KRY 2IM<"V.$@W@^BNEVKA& M^C?J8";6#3K:@+41K4T6=>(>-V"LV^R&%H]$\ZHD)?]67!;Y8R)2WZ:3![8X M:>0N#",66S'A <7*WV$-"4T,:*TN*@0V^H9\;I=+$]$111A'J;I_,[Z6/HH/T4=FQ/'$?13I]%!T 2]P9! EC2)S @9%M(^;'B(:Z M.R\2E7<]Q7W*QV.)1V"IY7Z?)[@#QO>")3X(EOC]L<0Z6.(16)Y5$0M.SG+6 M.9UE#H&113G$R*&>YS+JHUB5Q&;@ \-W5A^!0@M48NJHM;SOILO4D1Y0BF:T M\)%E;D1,*]!DD,C2;W(A?=P A?R1%Y^B95D06FZSX'L6C'#L04Z9C9W8$3S8 MRBPT(Q\:ADH+_'>C]C\-'%K^%7@P=:4)A*HA/21DR9LQT8HT'10R RTJI OT ML=A,JG9?TR!P9."$/:4 8K:5!KJU,W4*;= MZ.W'O!Y_9KZU(-QMRXC$@;"3X;C;6I-)A=6F&Q=G(EY!TG,1\?D_O#/&9?OB MHY*#.&2.%[AA[,>!K_R]MU1AF@V+M2BH58&0U=VHV*Z+ZB;%"+=&&Q3J1@TV M)GK,C-B4V(XX\89$CZ'N9D3?PM'][WRY?.#%0!?T_ @&7H@@D^=S)B(G\?H:'?G0)0T9)$YD0X]PZEI>9/% <[JE1VF:;BK$05O=88ON=WR;5_E%6RF8] M?1]#4GU_;L5.%*)(?!R-E#NP3& :2-\T-6<]I351)=+N"5'\>Z.IE$>6=OX(08@Q#PBWHHH"BV W(&M% M/C!,:RVP$E.'J.U^-SW&GO2P4;2CA8LT=2-.VI$F T1JH$F&?(%IMSG/:%[< MYT7=P>IYL+/\07R\?)%]-\U)" /,?$@8<9B-$/75+RQ5T)NF%[52:,P=KA/1 M_#Y;I8RJ_6IOQ3%J7Z/J8M#3E-R.:''#\2?N>$IFNPU0[6GFEQ4A'%TG9=J] MI*AJB=SED"%F(4J(0QG2O:1H$_S07;'2 'D,$/YG]"^P4=>_GNBU&+MY'6-1 MLTEJNC.ZD&C;QJB+B%Z#37X!T;8-V<5#G34CIRHO\V5)TK^2>UG#]#T'1A$6 M&,6.98N/;6%$/*.QRI;,-'WR=;QPI0V$N%%OE!9*M26.M6_4";6=F\]52HV- M'ZQLAWV?R4JIM=[12OGJD7!60VK?BNO\*=LF$\N MQ5,[H\TV@4$0(!B$=AAXEN=0]6[8#'Q@T%ZGMRHM_=FTVOING$P-Z3&DYL5H M_*R9^*BILSK0Y,-FS?1E,V:MQ_M :%;T0MPZ_;"Y)UG]?>O3#_\'4$L#!!0 M ( )*@&5T!@Q$#- 8 -@U 5 &UL MU9M;4]LX%,??^13>[.N*2+)\$5/HL&F[PRQM&:#3SKYT=#E*/'7LC&P@?/N5 M#>&2!.KB=")>H)!%]+^R.[%,%) M+FI3VBE"!^UAHW)V;;/QI XHIO%BV&*OW<-$X)!K0").!4HH:"2UX$CB6!J( M$TAX^-=X3VLI,*<2<28-8IR'2(24(0&1 AHJK6G8GC3/BA][S8L4%00NO*)J MO^X/)G4]VQL.KZZN=N?2YKNE'0\IQN%P,7IP.WR^,OXJ;$<3SOFPW7LWM,K6 M#72G)<-O'X_/U 2F F5%58M"-0:J;*]J-QZ72M2MZC_U*WAR1/,-+8:A9A,B M%(5D=U[IP<%.$-S(8RJ&YY9J!PM;:#';L/M.1IK MO^@$S&LH--Q$M3A]7JI'@_)&T](NCLR%A+S=^EU#]KT]\Z&L:BM4_7V).Z8, M$A%/$4\Y45KA.(GUXY@;?ROG<)N""M3NN+P4>_TPF8=6!:758-VDL3 GK'J4 MV%5<;T<,9\*Z$R$UR?([C8TMIYO(55UN0+F;M#AW!X&+VH"UH(]OLO)D<&UD MM9M*H1W9)^/OBSJKKT]AG#4"%/4G,5WQGS$W^5'&4:R,X& 8YHGLE?EU5CL1 M0/TEH+>27I!PY)9D.RMM*_R9TQ]&Y451V^M1J5?" >U6T%@F*&81P<"EX#+> M !C/.M&)D]!W3C:GLQ?8?,AR^'0QE6"7?><0(R&91HW;FJA4A&(3C-Q;[ 0$ M\QV(%RKH1?;/Q?Q(.ZTRD]U4FNL#P<)5TC1Q56,D#0^I9H+V*WR>-=^)B\AW M+C:AK1>0'&KM4E#=OKD2'& M:Q6E22K2WP)&V F,]/6!\6N:^@3&R'W\;,_+JV)E-8P($HQ1%PR6*8^D5"%L M#HM[PYV@X*\$BA?JZ1,2[9749WMBR\NL4"L74A%A*%6*NRI)BRA*F &@F^-B MR7JWGA9^)73TD=8G1$[*JA;Y?]ELW94V#;&[TJ8Q,C'AH(%)Q=7F 'EDNQL> M'O<\-R3KEN%H9KU#"V*=WU$:(;?X:42%25F8RI#V['P^M-8- (];GB^6;LLI M;VZ(Y2>3LGBRXR*;6WZ1F\LBC2-(Y::[8;"!YW+_N+N64:SLH\4UF= M%>./KL"QF'<,"Y8O_L=RTW*O&V%Q10%VY1O"94GF=U MOE(9)Q(CSK1".@6>)HJ$:8S[+2=+%KOAX'&OLI>$6T[_N17-,XUGUU-9KJR! MW/F<2J*=%HDRAB0XZ5E*/#+7+?$>]R-?+IXG/_KW,H M2950G!KM%KF-_/ ?6NWV')7'74GK1;7P_!3MV*/]CRZMZXA:WF2BNE\,0 M5"!I*$&A8)(GB@)+^BT%SQCO!H;W_<;^PFZ9CT-7X>BFROF0B_&RXRGG2 "+ MD,(T#B.(I;MD[D7$(W/=&/"XY?AR\;R8%4;.@@YW_ 5!+ 0(4 Q0 ( )*@&5V$AQ?VI!( *=Q 9 M " 0 !S<'ER92TR,#(V,#@R-7AE>'@Y.3$N:'1M4$L! A0# M% @ DJ 97?T,?D=3' I,H !$ ( !VQ( '-Y'-D4$L! A0#% @ DJ 9 M78F\A/7*"0 KUP !4 ( ![C$ '-YL[ !S>7)E+3(P,C8P.#(U7W!R92YX;6Q02P4& 4 !0!+ 0 &4D( end XML 16 syre-20260825_htm.xml IDEA: XBRL DOCUMENT 0001636282 2026-08-25 2026-08-25 false 0001636282 8-K 2026-08-25 SPYRE THERAPEUTICS, INC. DE 001-37722 46-4312787 221 Crescent Street Building 23 Suite 105 Waltham MA 02453 617 651-5940 false false false false Common Stock, $0.0001 Par Value Per Share SYRE NASDAQ false